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Summary Osteoporotic fractures are common and account for an important medical impact
and high induced health-related costs. The most common fracture sites are the vertebra, wrist,
proximal humerus and proximal femur. Osteoporosis must beneﬁt from a medical treatment
after a fragility fracture. This management is currently insufﬁcient in France, although diagnos-Risk factors;
Treatment;
Vertebroplasty
tic tools (DEXA scan), effective treatments and guidelines are available and have been widely
disseminated. Orthopaedic and trauma surgeons must emphasize to patients with a fracture
that they need to consult their general practitioner or rheumatologist to decide how their
osteoporosis will be diagnosed and treated.
© 2011 Elsevier Masson SAS. All rights reserved.
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steoporosis is the most common brittle bone disease. It
s deﬁned as ‘‘a bone disease characterized by a reduc-
ion in the mechanical strength of bone leading to increased
racture risk’’ [1]. Fragility fractures, which occur sponta-
eously or after a low-energy trauma, are a complication
f progressive loss in bone mass and changes in bone
icro-architecture. The most common fracture sites are the
ertebra, wrist and proximal femur.
Because of high prevalence, signiﬁcant morbidity,
dditional mortality and socioeconomic consequences,
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ax: +33 1 49 95 86 31.
E-mail address: philippe.orcel@lrb.aphp.fr (P. Orcel).
I
f
8
h
l
a
v
a
877-0568/$ – see front matter © 2011 Elsevier Masson SAS. All rights re
oi:10.1016/j.otsr.2011.10.002steoporosis is a public health concern for all physicians,
specially for surgeons who are treating a patient at the
ime of fracture. Yet, osteoporosis is too often a disease
hat is trivialized and lumped into the aging phenomenon,
hich leads to insufﬁcient diagnosis and treatment.
steoporosis and fragility fractures
t is estimated that one out of every two women will have a
racture between menopause and the end of her life. After
0 years of age, 70% of women have osteoporosis and 60%
ave had one or more fractures. Osteoporotic fractures are
ess common in men (about 15% of men above 50 years of
ge have had fractures) but they can be more serious [2].
Except for the skull, cervical spine, ﬁrst three thoracic
ertebrae, hands and toes, a fragility fracture can occur
t all bone sites. A low-energy trauma is deﬁned as a fall
served.
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DMedical management following an osteoporotic fracture
from standing height or a maximum of 50 cm, either during
walking or after having come to a stop. Osteoporosis can also
increase the likelihood of a fracture during a high-energy
trauma. Bone cracks (incomplete fractures without corti-
cal breach) can also be fragility fractures, although some
of them are associated with excessive mechanical load-
ing that leads to bone failure (fatigue or stress fractures).
Recent data suggests that fractures occurring in adolescents
or young adult result in a greater risk of osteoporosis after
the age of 50 [3,4].
Fractures of the proximal femur are the most serious;
the yearly incidence in France is estimated at about 70 000.
These fractures are associated with signiﬁcant morbidity and
mortality, with elderly subjects often losing their autonomy
and having a two to four times greater risk of dying within
a year than the general population. This increased mortal-
ity rate with all types of fractures is particularly evident
in men and women above 75 years of age [5]. The inci-
dence of vertebral fractures is difﬁcult to evaluate because
they are often mildly- or non-symptomatic (estimated at
150 000 per year in France). We are often unaware of these
fractures (only 1/3 are diagnosed), which puts emphasis
on the importance of clinical (height, kyphosis of thoracic
spine) and radiological screening when a menopausal women
presents with atypical and persistent back pain. The inci-
dence increases with age: 5.5 per 1000 people/year in
women 55—59 years of age to 29.3 in women 75—79 years
of age. The risk of recurrence is high. Women who have
had a vertebral fracture are ﬁve times more likely to have
another one within a year [6]. This risk, also seen with
non-vertebral fractures, is greatest in the two years follow-
ing the ﬁrst fracture in menopausal women [7]. There are
about 35 000 distal radius fractures per year. They result
in a signiﬁcant transient functional disability and can be
complicated by complex regional pain syndrome. As with
all vertebral fractures, these ‘‘sentinel fractures’’ are a
warning of other fragility fractures and should trigger a
search for an underlying osteoporotic disease. This approach
could avoid the subsequent occurrence of more serious
fractures.
After 65 years of age, one in three women will fall and
5% of these falls will lead to a fracture, with 1% being prox-
imal femoral fractures. Preventing falls should be a priority
to reduce fracture incidence. Known risk factors for falls
should be evaluated during the initial clinical examination:
visual problems, neuromuscular and orthopedic problems,
intake of psychotropic medicines or medicines that induce
orthostatic hypotension, obstacles in the patient’s home.
Recommendations for the prevention of falls in elderly
patients with a management algorithm were developed by
the American Geriatrics Society in 2001 [8].
Insufﬁcient management
After a fracture, the osteoporosis management rate (diag-
nosis and treatment) is very low in all countries.A study performed with British general practitioners
found that only the occurrence of a vertebral fracture
increased the prescription (rate) of anti-osteoporosis drugs
in the year following the fracture [9]. In France, the guide-
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ines, which non-specialists ﬁnd to be very complex, will be
pdated soon. A study performed in 2007 with 2658 French
eneral practitioners (APOTEOS) found that these physicians
ook the risk factors outlined in the French AFSSAPS guid-
nce into consideration when determining the appropriate
reatment [10].
Cuddihy and co-workers monitored women above 45
ears of age who had a distal radius fracture for an average
f three years (range of 1 to 6.7 years). This study found
hat only 18% were treated for osteoporosis, although 83%
ad consulted with a physician in the year after the fracture
other than the orthopaedic consultation) [11]. Similarly,
iagnostic evaluations in this population are quite rare: only
% of patients had a DEXA scan performed within one year of
he fracture. Another retrospective study found that treat-
ent (HRT, calcitonin, bisphosphonates) was prescribed in
4% of cases after vertebral fracture and in only 21% and 23%
f cases after proximal femur and distal radius fractures,
espectively [12]. Three of four patients were not being
reated before the fracture and 14% received treatment
fter. This lack of management, most evident in osteoporotic
omen with fractures, also exists in the male osteoporotic
opulation. A study found that only 7% of men with an
steoporotic fracture are being treated for osteoporosis
13].
However, there are signs of progress in more recent
ublications. Gardner and co-workers evaluated an active
rotocol that aimed at improving management after prox-
mal femur fracture in 80 patients hospitalized in the
rthopaedic unit [14]. Patients who were educated about
steoporosis during their hospital stay were given a DEXA
can and treated more often than patients who were dis-
harged only with a brochure on fall prevention (42% versus
9% in the second group).
Three very recent publications found that management
as improved after distal radius fracture. If a DEXA scan
as prescribed while a female patient was still in the
rthopaedic unit for a distal radius fracture, the likelihood
f therapeutic management increased 2.5 times [15]. When
he intervention was made later on, within 6 months of the
istal radius fracture, and targeted general practitioners,
wice as many DEXA scan were prescribed (53.3% vs. 26%)
nd therapeutic management increased three-fold (28% vs.
0%) [16]. A Canadian study with a similar approach conﬁrms
his data and suggests that the persistence of treatments
eing prescribed to these female patients was very good
more than 80% after one year) and that the strategy has
positive impact on health economics: reduction in costs,
mprovement in quality of life [17].
These data should encourage orthopaedic and trauma
urgeons to direct fragility fracture patients to their general
ractitioner or another facility to manage the osteoporosis.
ccess to these ‘‘fracture channels’’ depends on surgeon
otivation and could be facilitated by automated processes
education by nurses, mailing, etc.).
iagnostic and prognostic approachvaluating fracture risk is pivotal to the treatment deci-
ion. It is based on the evaluation of clinical risk factors
nd measurement of bone mineral density (BMD).
862 P. Orcel, T. Funck-Brentano
Table 1 Causes of secondary osteoporosis.
Endocrine diseases
Hypercortisolism
Hypogonadism
Hyperparathyroidism
Prolactin-secreting pituitary adenomas
Hyperthyroidism
Insulin-dependent diabetes
Acromegaly
Inﬂammatory and systemic diseases
Chronic inﬂammatory rheumatoid diseases (rheumatoid
arthritis, spondyloarthropathies)
Mastocytosis
Digestive disorders
Gastrectomy
Inﬂammatory enterocolopathy
Extended intestinal resections
Malabsorption, malnutrition
Chronic severe liver disease
Neoplastic diseases
Multiple myeloma
Metastatic cancer
Chemotherapy for cancer
Genetic disorders
Lobstein disease (osteogenesis imperfecta)
Connective tissue diseases (Ehlers-Danlos disease, Marfan
syndrome, elastorrhexis)
Homocystinuria
Hemochromatosis
Drugs
Corticosteroids (no consensus on inhaled corticosteroids)
GnRH antagonists
Aromatase inhibitors
High doses of thyroid hormones (TSH suppressing)
Extended heparin treatment
Chemotherapy for cancer
Lithium
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Table 2 Risk factors for fragility fractures (from the French
AFSSAPS).
Age
T-score for the lumbar spine and/or proximal femur
Personal history of fracture
Current or previous corticosteroid treatment
History of proximal femur fracture in ﬁrst-degree relatives
Low body weight (body mass index < 19 kg/m2)
Reduction in visual acuity
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to the normal curve of the same gender and race in the gen-Antidepressants, proton pump inhibitors (?)
iagnostic investigation is absolutely necessary
ut before this step, it is essential to look for a local
ause for the bone brittleness (tumour or osteolytic dys-
lasia) or for a systemic reason for the fragile bone disease
Table 1). The priority is to rule out a tumour (especially
yeloma), then osteomalacia, before looking for other rea-
ons for the bone fragility. The ﬁrst series of tests (calcemia,
hosphatemia, creatininemia, alkaline phosphatase, calci-
ria over 24 hours and 25-OH vitamin D) must be normal in
ases of post-menopausal or idiopathic osteoporosis. This
inimum screen however is not ofﬁcially recommended.
onversely, any abnormal ﬁnding in this screen will direct
he second round of tests (PTH, TSH, testosterone, LH and
SH or prolactin, cortisol, iron saturation coefﬁcient and
erritin, etc.).
Spinal X-rays should be performed if the patient presents
ith pain or is 4 cm shorter in height than when he/she
as a young adult [18]. These are used to look for verte-
ral fractures and signs of malignancy. With the slightest
e
t
sNeuromuscular or orthopaedic problems
Smoking
uspicious sign (cortical lysis, dissolving pedicle sign, signif-
cant retreat of the posterior wall or asymmetric fracture),
econdary examinations (MRI, CT scan or bone scan) will
elp to decide on and guide a bone biopsy for a pathology
iagnosis.
racture risk evaluation to decide on treatment
he decision to start an anti-osteoporosis treatment is based
n an evaluation of fracture risk through a careful analysis
f clinical features (risk factors) and BMD measurement. The
isk of recurrence must be evaluated with a current fracture,
nowing that the risk is higher than without a fracture. This
ituation often requires that an osteoporosis treatment be
rescribed for secondary prevention.
linical evaluation
certain number of clinical risk factors, both intrinsic and
xtrinsic to the patient, must be considered when determin-
ng the individual risk of a vertebral or peripheral fracture.
ypical clinical factors to evaluate are age, gender, per-
onal and family history of osteoporotic fracture, history
f extended cortisone treatment, low body mass index and
moking. A list of the main risk factors has been established
y the French AFSSAPS (Table 2). Other than corticosteroids,
he intake of aromatase inhibitors and GnRH analogues must
e investigated, as these treatments can accelerate bone
oss and increase fracture risk.
EXA scan to measure BMD
dual-energy x-ray absorptiometry (DEXA) scan is the gold
tandard method to evaluate bone mass. Measurements at
he lumbar spine (L1 to L4) and proximal femur have been
hosen as they are the most reproducible and narrowly cor-
elated to the fracture risk [19]. This is a simple, reliable,
eproducible, non-invasive, inexpensive examination that is
eimbursed in France for the indications approved by the
rench HAS (Table 3). One of the validated indications in men
nd women is a history of fracture, as long as the fracture
as non-traumatic. The measurement of bone mineral den-
ity (in g/cm2) is used to quantify bone loss and deﬁne bone
tatus relative to thresholds deﬁned by the World Health
rganization (WHO) (Table 4). A patient’s BMD is comparedral population and used to deﬁne the Z-score (comparison
o the average value for subject of the same age) and T-
core (comparison to young adult subjects, which reﬂects
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Table 3 DEXA indications that are approved by the French
HAS and reimbursed by the French National Health Insurance
since 2006.
Indications for the general population
Disease or treatment that induces osteoporosis
On-going « systemic corticosteroid therapy », prescribed
for at least three consecutive months, at a dose equal to
or above 7.5mg/day of prednisone equivalent (preferably
at the start of treatment)
Documented history of long-standing hypogonadism
(including surgical [orchidectomy, ovariectomy] or
drug-induced [extended GnRH agonist treatment]
androgen or oestrogen deprivation), untreated progressive
hyperthyroidism, hyperadrenocorticism, primary
hyperparathyroidism, osteogenesis imperfecta
Signs of osteoporosis
Discovery or radiological conﬁrmation of a vertebral
fracture (deformation of a vertebral body) without known
trauma or apparent tumour
Personal history of peripheral fragility fracture (one that
occurs without a signiﬁcant trauma — skull, toe, ﬁnger and
cervical spine fractures are excluded)
Additional indications in menopausal women
History of « systemic corticosteroid therapy », prescribed
for at least three consecutive months, at a dose equal to
or above 7.5mg/day of prednisone equivalent
Body Mass Index (BMI) < 19
History of femoral neck fracture without major trauma in a
ﬁrst-degree relative
Menopause before 40 years of age, independent of the
reason
When osteoporosis signs are present, current recommendations
advocate the investigation of a disease responsible for secondary
osteoporosis, or a tumour or traumatic cause for the fracture.
No matter the context, DEXA is only indicated if the results of
the scan can a priori lead to a change in patient management.
DEXA is not indicated if the woman is undergoing hormone
replacement therapy (HRT) with doses that are recommended
Table 4 Diagnostic classiﬁcation of osteoporosis with
DEXA.
Normal
BMD less than 1 SD below a young adult
(T-score >−1 SD)
Osteopenia
BMD between −1 and −2.5 SD that of a young adult
(−1 SD >T-score >−2.5 SD)
Osteoporosis
BMD more than 2.5 SD below that of a young adult
(T-score <−2.5 SD)
Conﬁrmed osteoporosis
BMD more than 2.5 SD below that of a young adult and
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brings up problems related to treatment decision thresh-
olds. This tool is now mostly used in pharmacoeconomic
studies to establish the cost-efﬁcacy threshold for each age
range. Reimbursement conditions could be determined by
Figure 1 Change in bone mineral density with age. An aver-
age curve with +1 and −1 standard deviation boundaries is
shown. Normal (green), osteopenia (orange) and osteoporosisto prevent osteoporosis (and not only to relieve hot ﬂash symp-
toms).
peak bone mass). By convention, osteoporosis is deﬁned by
the WHO as a T-score (at the lumbar spine or hip) lower than
−2.5 [20]; osteopenia is present when the score is between
−1 and −2.5 standard deviation. Normal subjects have a
T-score above −1 at both sites (Table 3 and Fig. 1).
To be reliable, this measurement must have been carried
out by a trained operator and performed on a scanner sub-
ject to regular quality control. Knowledge of interpretation
traps is needed to avoid wrongly classifying a patient into an
inappropriate bone status category. It would be ridiculous to
interpret DEXA results without knowing the patient’s clinical
context.
Evaluation of individual fracture risk
The drawback of this approach is that the risk is not quanti-
®ﬁed on an individual level. A new tool, FRAX , created from
multiple international databases at the request of the WHO,
calculates individual fracture risk as a function of the pre-
viously mentioned factors (Fig. 2). Its main beneﬁt is that
(
y
l
ipresence of one or more fractures
(T-score <−2.5 SD + fractures)
isk is quantiﬁed by determining individual probability of
racture at 10 years, either for ‘‘major’’ osteoporotic frac-
ures (femoral neck, vertebra, wrist, proximal humerus) or
peciﬁcally for the femoral neck.
However this tool has certain limitations that should be
entioned. First, from a technical point of view, the bone
ineral density measurement site chosen for the FRAX® is
he femoral neck. There is often a conﬂict between the
emoral neck values and typically lower spine values, espe-
ially in younger menopausal women. The femoral neck
easurement is also less reproducible. Second, the fracture
istory entered into the FRAX® does not take into account
he type of fracture (vertebral and hip fractures are known
o have a greater effect on the future risk of a new frac-
ure) nor the number of previous fractures (correlated to the
isk of future fractures, especially for vertebral fractures).
he cumulative corticosteroid dose is not considered, which
imits the use of the FRAX® in patients with chronic inﬂam-
atory diseases. Finally, the interpretation of the resultsred) areas are shown. The result of a female patient nearly 70
ears old is shown on this curve to demonstrate how to calcu-
ate the scores: for this patient, the Z-score is −1 and T-score
s −2.6.
864 P. Orcel, T. Funck-Brentano
Figure 2 Homepage to access the online FRAX tool. This tool is used to calculate the individual fracture risk and is available
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oor free at www.shef.ac.uk/frax. The FRAX is used to calculate
racture occurring.
he results of these studies. The evaluation of individual risk
ill always be estimated from epidemiological data [21].
espite its limitations, the FRAX tool is an important step
owards an objective approach to the evaluation of fracture
isk in an osteoporotic patient.
ow about biological markers of bone remodeling?
iological bone markers such as total and bone-speciﬁc
lkaline phosphatase, osteocalcin (for formation) and type
collagen fragments (CTX for resorption) are reimbursed
y the French Social Security. However, their role in the
iagnosis and evaluation of fracture risk has not yet been
etermined [22]. Insufﬁcient published data exists to show
hat these tests are clinically useful to monitor treatment
fﬁcacy. They could however identify patients who are not
aking their drugs or who have absorption problems (espe-
ially for oral bisphosphonates), as these tests are more
ensitive and able to detect changes earlier than DEXA. After
fracture, the level of bone remodeling markers generally
annot be interpreted because of increases related to the
racture callus. These levels can be elevated for 6 to 12
onths.
he risk of falling should also be evaluated
his evaluation should be done during every initial survey of
n osteoporotic patient, especially if a fracture has already
ccurred. Falling is a very common contributing or causal
actor. Many risk factors for falling have been identiﬁed in
pidemiological studies and two are on the French AFSSAPS
ist of fracture risk factors: neuromuscular and orthopaedic
roblems and reduction in visual acuity. Balance problems
a
t
t
m10-year probability of a hip fracture or signiﬁcant osteoporotic
especially iatrogenic) and obstacles at home are often the
ause of falls and fractures, especially in elderly subjects.
he use of preventative measures to correct these factors
ill help to diminish fracture risk.
one quality, the black hole of osteoporosis evaluation
one quality is not only determined by its mineral density,
ut its structure (micro-architecture of the trabecular net-
ork, thickness of bone cortex, amount of mineralization in
he protein matrix, etc.); both determine bone mechanical
roperties [23]. These qualitative parameters seem to be
elated to fracture risk. Non-invasive methods to evaluate
one quality (micro CT, high-resolution MRI, etc.) are being
ntensively researched but are not yet validated.
reatment methods
he goal of osteoporosis treatment in a patient who has had
fracture is to reduce the risk of a new fracture, either
ertebral or peripheral.
There have been signiﬁcant advances in the treatment of
steoporosis in the past 15 years. An increasing number of
olecules with various mechanisms of action, proven efﬁ-
acy, a good efﬁcacy/safety ratio are now available to be
sed within the framework of the French AFSSAPS recom-
endations, which are currently being updated. The choice
f the ﬁrst drug, monitoring and duration of treatment
nd questions related to observance (adherence and persis-
ence) are still being debated. Treatment strategies require
hat the bone deﬁcit be treated with health, diet and drugs
easures and that falls in older subjects be prevented.
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Healthy and diet measures
Calcium and vitamin D deﬁciencies, very common in the
French population, must be systematically identiﬁed with a
validated self-questionnaire (Fardellone questionnaire) on
the dietary intake of calcium and through an assay of the
stored form of vitamin D, 25 hydroxy-vitamin D (25 OH-D),
preferably the sum of 25 OH-D2 and 25 OH-D3.
Vitamin D deﬁciency is very common in the elderly; this
high prevalence has been known for a long time and is asso-
ciated with a decrease in BMD (particularly because of a
parathyroid reaction) and increase in the risk of falling and
fracture, because of the important role of vitamin D in mus-
cle metabolism. This is particularly evident in patients who
have recently suffered a femoral neck fracture [24,25].
These observations are a powerful reason to screen for
vitamin D insufﬁciency or deﬁciency and to correct it. Any
insufﬁciency or deﬁciency must be addressed by changing
the diet or with an appropriate calcium and vitamin D sup-
plement. The target concentration of 25 OH-D is 75 nmol/L
(30 ng/mL); a vitamin D insufﬁciency and deﬁciency is
deﬁned as serum concentrations lower than 50 nmol/L
(20 ng/mL) and 25 nmol/L (10 ng/mL), respectively. The pre-
ferred and simplest way to address the problem is through
the intake of vitamin D3 of animal origin (cholecalciferol).
Different treatment schemes are possible, without one being
superior [26]. Vitamin D is available either in ampules that
can be taken orally or injected or as a combination of vita-
min D with calcium or a bisphosphonate. The recommended
daily intake of vitamin D is between 800 and 1000 IU, once
the initial insufﬁciency or deﬁciency is corrected. No supple-
mentation approach has been shown to be superior in cases
of deﬁciency. To ensure that the correction is adequate, an
25 OH-D assay can be performed one week after the last
ampule is taken [26]. Maintenance treatment is absolutely
necessary to keep 25 OH-D levels above 30 ng/mL. Adher-
ence can be improved by administering either 100 000 IU of
D3 every 2 or 3 months, or 800 to 1600 IU of D3 every day.
There is no risk of overdose with these doses of vitamin D.
Regular physical activity is recommended to maintain
satisfactory bone mass. It also has a beneﬁcial effect on
balance, muscle tone and an active role in preventing falls.
The repletion of vitamin D also improves muscle function
and signiﬁcantly reduce the risk of falls [27]. The recom-
mended exercise regime is a weight-bearing activity that
involves ground impacts, for example walking, for about 30
to 60minutes per day. In elderly people and those with a high
risk of falling (such as institutionalized people for example),
a hip protector could reduce the risk of proximal femur frac-
ture. Finally, removing modiﬁable extrinsic risk factors such
as smoking and excessive alcohol intake can be beneﬁcial.
Drug therapy
An indication for drug treatment is always the result of the
evaluation of individual risk factors, due to the reoccurrence
of a fracture, through the identiﬁcation of clinical factors,
along with the interpretation of the DEXA scan and poten-
tially supported by the FRAX tool mentioned above. The goal
of treatment is to prevent fractures. This treatment should
be considered as the management of a chronic disease. It
n
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s important to determine the patient’s motivation and to
eighten their awareness of problems with treatment adher-
nce, which can limit treatment efﬁcacy [28]. Almost one
f two patients stops their treatment after 6 to 12 months.
Currently authorized drug classes are divided according
o their action on osteoclast resorption, osteoblast forma-
ion or both.
ntiresorption treatments
elective estrogen receptor modulators (SERM)
nly raloxifen (Evista®, Optruma®) is currently available for
he treatment of postmenopausal osteoporosis. It slows bone
emodeling and prevents lumbar and femur bone loss in
omen who have recently entered menopause. Increases
n lumbar and femoral BMD are modest as the woman is
urther past menopause. Raloxifen (60mg per day) reduces
he risk of vertebral fractures but not peripheral fractures,
uch as the femoral neck [29]. Thus it is mainly indicated in
emale patients with an elevated risk of vertebral fracture
ut no signiﬁcant risk of femoral neck fracture, essentially
enopausal patients under 70—72 years of age. The risk of
roximal femur fracture increases rapidly above this age,
aking it preferable to choose another type of drug. Sys-
emic safety is good. Hot ﬂashes and leg cramps can be
ncomfortable for the patient at the start of treatment.
recent study has shown a preventive effect on estrogen-
eceptor dependent invasive breast cancer (HR = 0.56 [95%
I: 0.38—0.83). Conversely, there were no beneﬁcial car-
iovascular effects in terms of heart disease [30] and even
tendency towards increased mortality due to strokes
HR = 1.49 [95% CI: 1.00—2.24]) and increased risk of throm-
oembolism (HR = 1.44 [95% CI: 1.06—1.95]). There are no
ffects on the endometrium.
isphosphonates
isphosphonates are stable pyrophosphate analogues that
ncorporate and accumulate easily in the bone matrix. They
re mainly anti-osteoclastic agents. There are ﬁve com-
ercially available bisphosphonates. Etidronate (Didronel®)
as practically no usage as it has the lowest level of evi-
ence of efﬁcacy. Risedronate (Actonel®) and alendronate
Fosamax®) taken daily (5mg and 10mg respectively),
specially weekly (35mg and 70mg respectively) or more
ecently monthly (75mg risedronate on two consecutive
ays, once per month) reduce the risk of vertebral and
eripheral fractures [29]. Ibandronate (Bonviva®), at a
onthly dosage of 150mg or slow intravenous administra-
ion (20 to 30 seconds) of 3mg every 3 months, is indicated
nly for the prevention of vertebral fractures. Zoledronic
cid (Aclasta®), administered as a rapid infusion (15 to
0minutes) once per year, prevents vertebral and non-
ertebral fractures, including the hip. This bisphosphonate is
he only drug to be evaluated in an elderly population (men
nd women with an average age of nearly 75 years) with a
ecent femoral neck fracture. The treatment reduced frac-
ure risk by 35%, fracture risk of the contralateral femoral
eck by 30% and also reduced mortality by 28% in these very
rail patients [31].
The number of available administration modes makes
t easier to choose something that is convenient for the
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atient, thus improving adherence. Similarly, combinations
f alendronate with vitamin D (Fosavance®, Adrovance®) can
implify the treatment plan.
Safety is generally good, but absorption in the gut is
oor and can lead to oesophagitis. This mean that the drug
ust be taken while fasting, for example 30minutes before
reakfast, with a large glass of poorly mineralized or non-
ineralized water, without lying down or bending down, to
void reﬂux of the tablet into the oesophagus. They are
ontraindicated in cases of kidney failure with creatinine
learance less than 30mL/min, pregnancy and allergy. Cases
f jaw osteonecrosis have been reported with bisphospho-
ates in very rare cases. These observations are mainly for
isphosphonates administered intravenously on a monthly
chedule for the treatment of malignant osteolysis (mey-
oma, metastasis). The risk is extremely low in osteoporotic
eople. However, it is justiﬁed to verify that an oral-dental
xamination was performed the year before the treatment
nd to perform any required invasive dental care such as
xtraction, before the bisphosphonate treatment is started.
one formation treatments
eriparatide (Forsteo®)
his is a 1—34 peptide fragment of human parathyroid hor-
one. This teriparatide is a powerful bone-forming agent
hat is administered by daily subcutaneous injection. The
vailability of a preﬁlled injection pen makes it easier to
se, as patients can perform the injections themselves.
dministration of this treatment in menopausal women with
evere osteoporosis prevents about two-thirds of vertebral
ractures. It also prevents peripheral fractures, with a lower
evel of evidence, however no effect on femoral neck frac-
ures has been demonstrated [29].
This restricted-use drug (special prescription) is indi-
ated for 18 months in men and women with severe
steoporosis or glucocorticoid-induced osteoporosis, and
nly reimbursed in patients with at least two previous
ertebral fractures and a low bone mineral density (T-
core <−2.5).
ecoupling agents
trontium ranelate (Protelos®)
trontium ranelate is unique in that it simultaneously
mproves bone formation and reduces bone resorption, by
ecoupling bone remodeling in favour of bone anabolism.
trontium ranelate reduces the risk of vertebral and periph-
ral fractures in menopausal women and reduces the risk of
ip fracture in a sub-group of women above 74 years of age
ith low bone density [32]. This drug has the greatest level
f evidence in women above 80 years of age for all types of
ractures.
It is taken daily as a 2 g powder packet that is dissolved
n a glass of water. Because of its poor bio-availability,
t should be taken in the evening before bed, well after
eals. Safety is good, other than the occasional headache
r diarrhea at the start of treatment. A slight increase in
he risk of thromboembolism has been reported; this is not
contraindication but a precaution when used in patients
ith a risk or history of thrombosis. However, a very recent
v
a
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eevaluation of the drug by the French Drug Agency (AFSS-
PS) has led to the suspension of authorization of strontium
anelate in elderly patients (over 80 years), due to their
igher risk of thromboembolic disease. A few cases of hyper-
ensitivity with severe systemic affection (DRESS syndrome)
ere reported in late 2007. These occurred at the start of
reatment (ﬁrst six weeks). The treatment should be imme-
iately stopped if a suspicious skin rash appears.
ole of hormonal treatment in menopause
ormonal treatment during menopause slows or stops bone
oss due to oestrogen deﬁciency. The inhibitory action of
estrogens on osteoclasts slows down bone remodeling,
owever this effect is lost when treatment is stopped. To
revent fractures, the dose is higher than the ones used to
ontrol the hot ﬂash symptoms of menopause.
Recent data has shown increased mammary, venous
hromboembolic, coronary artery and cerebral vascular risk,
hich has raised questions about the multiple indications
or this treatment. Hormonal treatment during menopause
s indicated for signiﬁcant hot ﬂash symptoms, and pres-
ription duration is adapted to changes in these symptoms.
ith the availability of effective treatment alternatives,
his is no longer the ﬁrst line treatment for post-menopausal
steoporosis [33].
uture treatments
enosumab (RANKL antibody)
his new drug is the ﬁrst to bridge osteoporosis and bio-
herapeutics. Denosumab blocks the action of RANKL (RANK
igand, an osteoblast factor that drives osteoclast differen-
iation and resorption activity) and leads to a reduction in
one resorption. Denosumab reduces the risk of vertebral
ractures, non-vertebral fractures and especially femoral
eck fractures [34]. It is not yet commercialized in France.
nti-cathepsin K
athepsin K is secreted by osteoclasts into the resorption pit
nd is a key bone resorption enzyme. Blocking the action of
his enzyme slows down bone loss. A very speciﬁc inhibitor is
urrently being developed for osteoporosis, with promising
reliminary data.
steoblast differentiation promoting agents
ull length PTH (1—84) is being evaluated as an alternative
o the teriparatide. Not yet commercialized in France, it has
hown to be effective against vertebral fracture and could
lso be effective with weekly sub-cutaneous administration
nstead of daily.
Osteoblast growth factors such as IGF, BMP and FGF
re interesting bone anabolic treatment approaches. Acti-
ation of the Wnt/-catenin pathway is another potential
pproach, either by preventing -catenin degradation (with
ithium for example) or by blocking its inhibitors (anti-Dkk1,
nti-sclerostin, etc.).
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Table 5 Level of proof for the efﬁcacy of osteoporosis drugs relative to vertebral, non-vertebral and hip fractures.
Efﬁcacy relative to
vertebral fractures
Efﬁcacy relative to
peripheral fractures
Efﬁcacy relative to
hip fractures
Calcium+ vitamin D ND (−?) +/− +a
HRTb + + +
Raloxifen + − −
Alendronate, risedronate + + +
Ibandronate + − −
Zoledronic acid + + +
Teriparatide + + −
PTH 1—84c + − −
Strontium ranelate + + +d
Denosumabe + + +
a Low level of proof, studies are contradictory. Using this treatment in isolation is not recommended.
b Not indicated to prevent or treat osteoporosis in France.
c Drug has marketing approval, but is not commercialized in France.
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e Does not have marketing approval yet, but recent data publish
Treatment strategies: who should be treated,
with which drug and for how long?
Which patients should be treated?
In the context of osteoporosis management in a male
or female patient with a recent fragility fracture and
osteoporosis, treatment indications are broad but the
decision is always based on clinical judgment. Any patient
above 60 years of age with a history of signiﬁcant fracture
(vertebra, proximal femur, humerus) is considered as a
treatment candidate if the fragility state is conﬁrmed
by DEXA scan (osteoporosis or osteopenia). With a wrist
or other (rib, pelvis, tibia, metatarsal, etc.) fracture,
treatment is indicated in cases of osteoporosis conﬁrmed
by DEXA (‘‘all the more’’ if the T score is very low) and the
presence of other fracture risk factors. This is a situation
where the FRAX could be used to guide the clinician’s deci-
sion, based on the risk score provided by this tool. However,
the intervention thresholds have not yet been validated
in France (but will be proposed soon in the frame of the
revised guidelines). In younger persons, fracture risk is low
and the treatment indication must be carefully weighed.
Choice of treatment
As with most chronic diseases, osteoporosis treatment
involves an overall pre-treatment evaluation to educate the
patients, discuss with them the most relevant options and
agree on the ﬁnal decision, when possible [35].
In 2006, the French AFSSAPS published good prac-
tice recommendations for the therapeutic management of
osteoporosis as a function of different potential clinical
situations. This document is available on the website of the
French AFSSAPS. The proposals are based on the existence of
an associated fracture (excluding skull, cervical spine, hand
and toe fractures), age, bone density and other fracture risk
factors. The recommendations are currently being updated
r
t
s
aith a hip BMD T-score <−2.5.
o take into account new treatments and the individual frac-
ure risk evaluation provided by the FRAX tool.
Table 5 summarizes the efﬁcacy of current treatments in
he prevention of vertebral, peripheral or proximal femur
ractures. The choice must also take into account the moti-
ation for the treatment (long term and with no immediately
pparent beneﬁt), practical methods for drug delivery based
n patient preference, medical history, and compare these
ith the risk proﬁle of the osteoporosis drugs. Raloxifen has
he added beneﬁt of preventing breast cancer, even in high-
isk women [30], but it is contraindicated when a history
f severe thromboembolism exists. Strontium ranelate must
e used with care under these circumstances. In elderly
atients, fragile and dependent, annual zoledronic acid
nfusion ensures the treatment by avoiding the limitations
nd uncertainties of oral administration. All treatments
ust be avoided in patients with severe kidney failure
clearance below 30mL/min), however it will be possible
o use denosumab in the future in these patients.
In women above 75 years of age who have a rapidly
ncreasing risk of femoral neck fracture, raloxifen and iban-
ronate should be avoided as they do not address this risk.
Finally, regulatory aspects must be considered; the teri-
aratide is only reimbursed in patients with at least two
ertebral fractures. Prescribing it outside this framework
hould be avoided as its high price requires good reimburse-
ent coverage.
hat length of treatment?
he duration of osteoporosis treatments is not regulated.
t is based on observational efﬁcacy and safety data with
he maximum follow-up occurring during open-label tri-
ls. However we need to remember that this disease must
e managed over the long-term, which implies periodic
eevaluation to monitor the risk of fracture, especially if
reatment has been interrupted [36]. Raloxifen can be pre-
cribed without issue for 10 years or more. The logical
pproach is to stop when the risk of non-vertebral fractures
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egins to increase, thus after 70 to 74 years of age. Long-
erm data (up to 10 years) with the original bisphosphonates
ave been published and demonstrated good safety, which
ustiﬁes this length of treatment, even if some prefer a
horter treatment period such as ﬁve years. Indeed, the
ecently reported ‘‘atypical’’ subtrochanteric or diaphyseal
emoral fracture during longterm bisphosphonate treatment
ccur after a mean duration of ﬁve to seven years of
xposure to the drug. For the teriparatide, the maximum
reatment period is set according to the conditions of use:
urrently 18 months and probably 24 months soon. Since
trontium ranelate has only been commercially available
ince 2007, the question is not really relevant; however
-year efﬁcacy and 8-year safety data are encouraging.
These theoretical treatments durations must be put into
erspective relative to poor treatment adherence, which is
urrently the greatest barrier to the efﬁcacy of these treat-
ents. Monitoring osteoporotic patients is essential to verify
nd emphasize the importance of treatment adherence to
ptimize the chances of success.
reatment monitoring and patient follow-up
onitoring is an unavoidable practical challenge because
here are no markers for short-term treatment efﬁcacy.
Clinical monitoring must be linked, consultation after
onsultation, to verify adherence and safety of the pre-
cribed treatment and any supplements, observance of
ealth and diet rules and the absence of new fractures. A
eduction of 2 cm or more in height between two visits six
onths apart cannot be ignored and should lead to a request
or thoracic and lumbar spine x-rays to look for a vertebral
racture [37]. The occurrence of a fracture during treat-
ent should lead the physician to ask multiple questions:
oor treatment adherence or poor treatment intake (e.g.
ral bisphosphonate taken during meals or with calcium) or
reatment failure? If poor adherence to an oral treatment
s evident, an intermittent parenteral treatment could be
olution. Treatment failure is deﬁned as the occurrence of
non-traumatic fracture beyond the ﬁrst year of taking the
ame osteoporosis drug. The treatment must be changed.
DEXA measurement is not indicated to monitor an anti-
steoclast treatment, because a measurement taken within
years of treatment initiation has little chance of detect-
ng a signiﬁcant change. The rapid increase in bone mineral
ensity induced by the teriparatide or strontium ranelate
ould allow an early evaluation to be considered, for exam-
le after the ﬁrst year of treatment, however this indication
s not approved in the French HAS reimbursement rules.
The role of biochemical markers of bone remodeling as a
onitoring tool has not been established, however in certain
ases it could identify patients with adherence or absorption
roblems.
onclusions
onsiderable progress has been made in the diagnostic and
herapeutic management of osteoporosis. The primary goal
s to treat patients with a history of fragility fractures, which
ould certainly reduce the medical, social, psychological
nd personal impact of osteoporotic fractures. Recent dataP. Orcel, T. Funck-Brentano
uggest that better access to DEXA for diagnosis and the
vailability of effective treatments could start to shift the
ncidence curves for certain osteoporotic fractures — this is
n important issue for us in the next 20 to 50 years!
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